CEL-SCI Corporation

Informe acción NYSEAM:CVM

Capitalización de mercado: US$53.7m

CEL-SCI Resultados de beneficios anteriores

Pasado controles de criterios 0/6

CEL-SCI's earnings have been declining at an average annual rate of -2.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 72.6% per year.

Información clave

-2.2%

Tasa de crecimiento de los beneficios

6.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 17.0%
Tasa de crecimiento de los ingresos-72.6%
Rentabilidad financiera-343.5%
Margen neton/a
Última actualización de beneficios30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Market Sentiment Around Loss-Making CEL-SCI Corporation (NYSEMKT:CVM)

Apr 29
Market Sentiment Around Loss-Making CEL-SCI Corporation (NYSEMKT:CVM)

We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth

Mar 01
We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth

What Does CEL-SCI's (NYSEMKT:CVM) CEO Pay Reveal?

Jan 25
What Does CEL-SCI's (NYSEMKT:CVM) CEO Pay Reveal?

Breakeven On The Horizon For CEL-SCI Corporation (NYSEMKT:CVM)

Dec 21
Breakeven On The Horizon For CEL-SCI Corporation (NYSEMKT:CVM)

Desglose de ingresos y gastos

Cómo gana y gasta dinero CEL-SCI. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NYSEAM:CVM Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 240-2990
31 Mar 240-3090
31 Dec 230-3190
30 Sep 230-3290
30 Jun 230-3490
31 Mar 230-3590
31 Dec 220-37100
30 Sep 220-38110
30 Jun 220-37110
31 Mar 220-36120
31 Dec 210-37130
30 Sep 210-37130
30 Jun 210-34130
31 Mar 210-35130
31 Dec 201-33120
30 Sep 201-30120
30 Jun 201-30110
31 Mar 201-32100
31 Dec 190-2990
30 Sep 190-2280
30 Jun 191-3260
31 Mar 191-2660
31 Dec 181-2450
30 Sep 180-3260
30 Jun 180-2270
31 Mar 180-2070
31 Dec 170-2470
30 Sep 170-1460
30 Jun 170-1080
31 Mar 170-1080
31 Dec 160-1070
30 Sep 160-1280
30 Jun 160-2070
31 Mar 160-2180
31 Dec 151-25100
30 Sep 151-35140
30 Jun 151-32150
31 Mar 150-30150
31 Dec 140-31140
30 Sep 140-28110
30 Jun 140-2380
31 Mar 140-257-5
31 Dec 130-1270

Ingresos de calidad: CVM is currently unprofitable.

Margen de beneficios creciente: CVM is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CVM is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.

Acelerando crecimiento: Unable to compare CVM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: CVM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rentabilidad financiera

Alta ROE: CVM has a negative Return on Equity (-343.45%), as it is currently unprofitable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado